12 Week Efficacy and Safety Study of Empagliflozin (BI 10773) in Hypertensive Patients With Type 2 Diabetes Mellitus
Status:
Completed
Trial end date:
2012-07-01
Target enrollment:
Participant gender:
Summary
This trial will evaluate safety and efficacy of BI 10773 in hypertensive patients with type 2
diabetes. Since hyperglycaemia and hypertension are key risk factors for both micro- and
macrovascular complications, assessment of both glucose and blood pressure lowering effects
of BI 10773 in hypertensive patients with type 2 diabetes could provide clinically highly
relevant, new information for the use of BI 10773